Personalized vaccine targets melanoma recurrence - Medical Xpress
Newly released phase 3 INTerpath-001 results show a personalized mRNA vaccine combined with pembrolizumab reduced the risk of melanoma recurrence or death at two years versus pembrolizumab alone after surgery, building on the phase 2 KEYNOTE-942 evidence that first established the approach. Sutter Health investigators Dr. Kevin Kim, chief of precision medicine, and Dr. Mohammed Kashani-Sabet, medical director of Sutter CPMC's Cancer Center, led Sutter's participation in KEYNOTE-942. Each vaccine is personalized using the patient's unique tumor genomic profile, training the immune system to recognize and attack cancer cells. Why it matters: this is the individualized neoantigen mRNA modality advancing from promising phase 2 data to large international phase 3 confirmation in the adjuvant melanoma setting.